Health

Oil and gas companies backed just 32 startup deals with a total estimated value of $1.23 in the first quarter of the year.

Technology is starting to make it possible to understand the complex interactions of the microbiome in more detail.

BiomeSense, a University of Chicago spin out, wants to create a 10m record dataset for the microbiome sector.

Sometimes called the “last organ under active research”, the human microbiome and therapeutics relating to it are attracting dollars and interest in the innovation community – albeit still from a low base.

A treatment for all lung diseases, a rose petal-inspired coating to make solar cells more efficient and a device to resuscitate newborns are among this month's picks.

Data centres need a revamp to allow for the high-speed data processing artificial intelligence requires — and light is key to the transition.

GSK remains an investor in the new $600m Fund II, but with a smaller financial presence as SR One positions itself to connect startups to multiple companies across the pharmaceuticals sector.

A small but growing number of CVCs are quietly reaching fund sizes of more than $1bn. When they get there, life changes in some ways.

The numbers of deals, exits and funding initiatives involving corporates continue a relative decline year-on-year. But there was a pause in the most recent quarter, when the fall is mostly in total dollar terms. The community appears to have weatherеd the SVB debacle successfully (at least for now).

We asked leading corporate venture investors what they look for. Knowing your competition and how you stand out is crucial.

From holograms and new collaboration platforms to dynamic pricing software, three investors told us what they are backing in the new world of work.